Intellia Therapeutics Stock News

We’ve been concentrating our portfolios towards our highest conviction names and so we haven’t done anything different.

The stock market and bond market remain historically overvalued today, however, the almost all-encompassing bubble has started to break. Learn more here.

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

Lessons from the past can guide investors if history is repeating.

CRISPR stocks will face make-or-break moments in 2022 as Big Pharma joins their quest to cure serious diseases with gene editing technology.

Intellia (NTLA) inks a licensing and collaboration deal with Kyverna Therapeutics for developing an allogeneic CAR T-cell therapy for autoimmune diseases.

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that the company is scheduled to present virtually at the 40 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET.

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CR

Both are making progress in a game-changing area.

While Intellia's (NTLA) pipeline is in early-stage clinical studies, its development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplar

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Illinois Municipal Retirement Fund acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 3,610 shares of the companys stock, valued at approximately $484,000. Other institutional investors and hedge funds have also recently added to or reduced []

Related Stocks: RGEN , DASH , NTLA , ABNB , MNDY , BIO , CRL , S , S , 0A8V , FRSH , FRSH , PINS , WIX , CSGP , NARI , ZEN , GH , 7974 , UBER , RNG , QTWO , 03690 , EQIX ,